SEC Form 4 · accession 0001237899-17-000034
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
George Yancopoulos
Officer — President & CSO · Director
Period of report
Dec 18, 2017
Accepted (ET)
Dec 20, 2017 · 4:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 18, 2017 | F | 257,850 | $386.90 | D | 422,762 | D | |
| Common Stock | holding | — | — | — | 323,777 | I | by GRAT | |
| Common Stock | holding | — | — | — | 176,223 | I | by GRAT | |
| Common Stock | holding | — | — | — | 5,702 | I | By 401(k) Plan | |
| Common Stock | holding | — | — | — | 64,058 | I | by Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).